Loading clinical trials...
Loading clinical trials...
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study to evaluate the efficacy and safety of ibrutinib in combination with rituximab versus placebo in combination with ritu...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pharmacyclics LLC.
Collaborators
NCT07545603 · Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, and more
NCT06149286 · Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
NCT06337318 · Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
NCT05006716 · B-cell Malignancy, Marginal Zone Lymphoma, and more
NCT06026319 · Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, and more
Southern Cancer Center
Mobile, Alabama
City of Hope
Duarte, California
Sansum Clinic
Santa Barbara, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions